Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, May 30, 2025 (HealthDay News) — For patients with BRAF <\/em>V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]), according to a study published online May 30 in the New England Journal of Medicine <\/em>to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.<\/p>\n Elena Elez, M.D., Ph.D., from Vall d’Hebron Hospital Campus in Barcelona, Spain and colleagues conducted an open-label study in which they randomly assigned patients with untreated BRAF<\/em> V600E-mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care consisting of chemotherapy with or without bevacizumab (158, 236, and 243 patients, respectively). Data on progression-free survival and an updated interim analysis of overall survival were presented.<\/p>\n The researchers found that progression-free survival was significantly longer with EC+mFOLFOX6 than <\/sub>standard care (median, 12.8 versus 7.1 months; hazard ratio for progression or death, 0.53). Overall survival was significantly longer with EC+mFOLFOX6 than with standard care in an interim analysis (median, 30.3 versus 15.1 months; hazard ratio for death, 0.49). The incidence of serious adverse events during treatment was 46.1 and 38.9 percent with EC+mFOLFOX6 and standard care, respectively; safety profiles were consistent with known profiles for each agent.<\/p>\n “The benefits with regard to both progression-free survival and overall survival with EC+mFOLFOX6 were observed across all the prespecified clinical subgroups, including in patients with liver metastases or with involvement of three or more organs,” the authors write.<\/p>\n Several authors disclosed ties to Pfizer, which funded the study, with support from Ono Pharmaceutical, Merck, and Eli Lilly.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n